Human mpox: global trends, molecular epidemiology and options for vaccination.
Pathog Glob Health
; 118(1): 25-32, 2024 02.
Article
en En
| MEDLINE
| ID: mdl-37715739
ABSTRACT
The eradication of smallpox and the cessation of vaccination have led to the growth of the susceptible human population to poxviruses. This has led to the increasing detection of zoonotic orthopoxviruses. Among those viruses, monkeypox virus (MPV) is the most commonly detected in Western and Central African regions. Since 2022, MPV is causing local transmission in newly affected countries all over the world. While the virus causing the current outbreak remains part of clade II (historically referred to as West African clade), it has a significant number of mutations as compared to other clade II sequences and is therefore referred to as clade IIb. It remains unclear whether those mutations may have caused a change in the virus phenotype. Vaccine effectiveness data show evidence of a high cross-protection of vaccines designed to prevent smallpox against mpox. These vaccines therefore represent a great opportunity to control human-to-human transmission, provided that their availability has short time-frames and that mistakes from the recent past (vaccine inequity) will not be reiterated.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Viruela
/
Vacunas
/
Mpox
Tipo de estudio:
Screening_studies
Límite:
Humans
Idioma:
En
Revista:
Pathog Glob Health
Año:
2024
Tipo del documento:
Article
País de afiliación:
Suiza